HEPA — Hepion Pharmaceuticals Balance Sheet
0.000.00%
- $5.92m
- -$5.50m
- 17
- 33
- 18
- 12
Annual balance sheet for Hepion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 13.9 | 40.7 | 91.3 | 51.2 | 14.8 |
Prepaid Expenses | |||||
Total Current Assets | 14.4 | 42.6 | 97.5 | 56.5 | 17.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.855 | 0.665 | 0.456 | 0.132 | 0.242 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 20.6 | 48.6 | 104 | 60.2 | 18.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.61 | 4.66 | 8.21 | 7.89 | 5.29 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.99 | 8.12 | 10.6 | 10.4 | 10.8 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 15.6 | 40.5 | 93 | 49.9 | 7.28 |
Total Liabilities & Shareholders' Equity | 20.6 | 48.6 | 104 | 60.2 | 18.1 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |